Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 55 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 12.81L
+3.31%-3.70%+61.03%+103.64% 7.06TCr
+0.04%+0.64%+50.65%+93.31% 6.61TCr
-1.03%+0.46%+8.14%-5.28% 2.8TCr
-2.41%-2.95%-9.77%+455.82% 2.65TCr
+0.30%-0.69%+63.18%+11.93% 2.64TCr
+1.02%+6.43%+269.42%+420.34% 2.04TCr
+0.74%+1.49%+35.38%-17.00% 2.02TCr
-1.91%-4.37%+13.33%+531.29% 1.6TCr
-1.50%+2.92%+43.50%+151.30% 1.37TCr
Average -2.48%+0.99%+59.43%+193.93% 3.2TCr
Weighted average by Cap. +0.47%+0.65%+56.67%+154.70%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14